News

Researchers have pinpointed Jagged-2, a signaling protein, as a potential therapeutic target for slowing or halting the progression of pulmonary arterial hypertension (PAH), based on a rat study. Suppressing Jagged-2 in a rat model reversed various processes that drive PAH progression, including inflammation and oxidative stress, a form of…

Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in people with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Tenax said its ongoing Phase 3 trial, LEVEL (NCT05983250), is expected to finish enrollment next year.

Uptravi (selexipag) may reduce blood pressure in the lungs of children with pulmonary arterial hypertension (PAH) and help them perform physical tasks, according to a meta-analysis. However, more long-term studies are still needed to confirm these benefits. The study, “Efficacy and Tolerability of Selexipag in…

A committee of the European Medicines Agency (EMA) has recommended expanding the indication for Winrevair (sotatercept-csrk), Merck’s approved injection therapy for adults with pulmonary arterial hypertension (PAH). Winrevair was approved in the European Union last year. It is currently indicated for use in combination with…

Having more severe bronchopulmonary dysplasia (BPD) — a chronic lung disease that occurs when a baby’s lungs aren’t fully developed — does not predict worse pulmonary hypertension (PH) in infants born preterm, according to a new study that used data from a patient registry. The researchers found that BPD is…

The U.S. Food and Drug Administration (FDA) has cleared Cereno Scientific’s request to launch a global Phase 2b trial of CS1, an oral therapy for people with pulmonary arterial hypertension (PAH). The company expects to begin enrolling patients in the second quarter of 2026, with top-line data anticipated…

People with chronic thromboembolic pulmonary hypertension (CTEPH) who have a high pulmonary arterial wedge pressure (PAWP) — a measure of pressure in the heart’s left atrium, which receives blood from the lungs…

Altered activity of a protein called PUM1 plays a key role in the development of pulmonary hypertension (PH), according to a new study done in animal and cell models. “Our study establishes PUM1 as a critical driver of PH pathogenesis [disease development],” the scientists wrote, adding that “this discovery…

Tiakis Biotech is set to advance its experimental therapy tiprelestat into a Phase 2 clinical trial for pulmonary arterial hypertension (PAH), after successfully finalizing the data package required for regulatory review. The planned study, dubbed ATHENA, will be led by Stanford University and will enroll about 90 patients…

Overproduction of the naturally occurring hormone adrenomedullin, or ADM, helped protect neonatal mice from experimental bronchopulmonary dysplasia (BPD) and related pulmonary hypertension (PH), a study reports. “These findings strongly support the potential of ADM therapy for infants with BPD-PH,” the researchers wrote in the study, “Adrenomedullin…

Two proteins associated with the aggregation and activation of platelets may serve as biomarkers of chronic thromboembolic pulmonary hypertension (CTEPH) severity and progression, according to a study conducted in China. The proteins, PAD4 and NOX2, were elevated in platelets of people with CTEPH compared with healthy individuals, suggesting they may…

Merck Canada has taken what it called a “critical step” toward making its approved therapy Winrevair (sotatercept-csrk) — which works to improve exercise capacity and reduce the risk of clinical worsening events in people with pulmonary arterial hypertension (PAH) — accessible to eligible patients in the country. The…